Search

Beyond vision loss: Why doctors should know about Charles Bonnet Syndrome

Over 250 years have passed since Charles Bonnet’s seminal essay, in which he described the symptoms of the syndrome that now takes his name [1]. Charles Bonnet Syndrome (CBS) describes the occurrence of visual hallucinations in people with significant visual...

Cutting-edge practice in glaucoma care: what, how and why?

More effective treatments and drug delivery modalities, implantable minimally invasive glaucoma surgical (MIGS) devices, as well as accelerating clinical research programmes, will transform the surgical and clinical management of glaucoma in the near future. There is also an ever-greater emphasis...

Well-presented scholarly research work will reduce chances of journal rebuttal

Submitting to an academic journal? Are you aware of the requirements and constraints of relevant copyright laws? Rod McNeil provides a guide for aspiring authors. Getting published in peer-reviewed academic and medical journals is not easy. But careful attention to...

Childhood glaucoma

When a child is given a diagnosis of glaucoma, the impact upon that child and their family is enormous; equivalent to the diagnosis of a cancer [14]. This previously published article (2019) outlines the knowledge, techniques and approaches that offer...

Newer generation IOL platforms designed for high-quality visual performance after cataract surgery

Expanding intraocular lens (IOL) capabilities provide broadening options, ranging from next-generation monofocal IOLs for basic cataract surgery, to specialised premium IOLs for lens-based presbyopia correction and astigmatism correction at the time of cataract surgery. Rod McNeil considers several newer alternative...

Retinoblastoma management update (part 2): treatment, screening and surveillance, long-term follow-up and new developments

Retinoblastoma treatment requires significant multidisciplinary input, but early detection through raising awareness remains key to improving outcomes. In the second article of a two-part series, Manoj Parulekar discusses retinoblastoma management, screening and research. This article has been published in two...

What’s new in wet AMD papers?

Paper presentations on neovascular (‘wet’) age-related macular degeneration (AMD) from the 16th European Society of Retina Specialists Congress, Copenhagen, September 2016, outline recent research directions evaluating the impact of vision loss on key health domains, patient preferences in the process...

Regulatory drug evaluations and expedited review initiatives: EU and US perspectives

The European Medicines Agency (EMA) and United States Food and Drug Administration (FDA) each conduct independent assessments of benefit-risk profile when evaluating applications to market new or modified medicines, and their respective decision-making is guided by distinct legislation, procedures and...

Blinking blepharitis has a lot to answer for…

Never ignore the small things’…someone once said. There is no doubt blepharitis is one of the most common eye conditions encountered daily, but with the typical pressures of a busy outpatient department, the management of more obvious, sight-threatening conditions necessarily...

COVID-19: Pete’s Bogus Journey

The author shares his personal experience of contracting coronavirus. I managed to body swerve COVID-19 for nine months. The Pfizer vaccine was being rolled out in my trust. I had my first inoculation booked in three weeks. I had survived...